Who are Lassogen's investors?

Lassogen's investors include Better Ventures Central Llc, First In Ventures, Playground Global.

How much funding has Lassogen raised?

Lassogen has disclosed $5.1M raised across 1 round.

Where is Lassogen headquartered?

Lassogen is headquartered in San Diego, US.

Lassogen

San Diego, US · Founded 2019 · Delaware corporation · 3 employees on LinkedIn · 3 known investors

Lassogen engineers lasso peptides — structurally unique 3D scaffolds — into therapeutics it calls Lassotides, designed to combine the strengths of antibodies and small molecules. The company develops these therapeutics to treat challenging diseases and disease targets inadequately addressed by existing approaches.

AI & Machine Learning Biotech

Founders & leadership

Mark J BurkNamed on SEC filing

Investors · 3

Better Ventures Central LlcOakland · $500K – $1.5M

First In VenturesMiddletown · $50K – $200K

Playground GlobalreportedPalo Alto · $1M – $20M

Reported raises · per SEC filings

Form D private placements

$5.1M disclosed across 1 round · 2020

▶$5.1MraisedSep 2020 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark J BurkExecutive Officer

Offering amount: $5.1M
Amount sold: $5.1M
First sale: Sep 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap

Rsc4 shared keywordsThe Royal Society of Chemistry is a professional membership organisation that connects the global chemistry community through partnerships, conferences, networks and publications. It sets standards for chemical scientists, promotes open access to scientific knowledge, and advocates for chemistry's role in addressing societal challenges including healthcare, environmental protection, and clean energy.

Versogen3 shared keywordsVersogen develops anion exchange membrane (AEM) electrolyzers that produce green hydrogen at scale for decarbonizing the energy, chemical, and manufacturing sectors. The company operates in the clean energy and hydrogen technology space.

Saliogen Therapeutics3 shared keywordsSalioGen Therapeutics was a genetic medicine company. The company is no longer operating.

Solugen3 shared keywordsSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.

Solid Biosciences3 shared keywordsSolid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.

SOLA Biosciences3 shared keywordsSOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins. The company uses its proprietary JUMP70 platform to restore protein homeostasis and deliver disease-modifying treatments.

Companies competing with Lassogen for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2021	$399.6K
National Institutes of Health (NIH)National Institutes of Health	Phase ISTTR	2020	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Lassogen Raises Seed Round to Develop Novel Therapeutics for Challenging Targetsbusinesswire.com · Oct 2020

Lassogen Raises $4.5M in Seed Funding - FinSMEsfinsmes.com · Oct 2020

The Crunchbase News Briefing: Tue., Oct. 13news.crunchbase.com · Oct 2020

Frequently asked questions

What does Lassogen do?: Lassogen engineers lasso peptides — structurally unique 3D scaffolds — into therapeutics it calls Lassotides, designed to combine the strengths of antibodies and small molecules. The company develops these therapeutics to treat challenging diseases and disease targets inadequately addressed by existing approaches.
Who are Lassogen's investors?: Lassogen's investors include Better Ventures Central Llc, First In Ventures, Playground Global.
How much funding has Lassogen raised?: Lassogen has disclosed $5.1M raised across 1 round.
Where is Lassogen headquartered?: Lassogen is headquartered in San Diego, US.